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Abstract:  
 We  present  the  case  of  an  80-year-old  man  who  was  admitted  for  anemia,  back  pain  and 
progressive weakness. After a workup of clinical and laboratory data, the final diagnosis was multiple 
myeloma.  The  bone  marrow  aspirate  revealed  53%  myeloma  cells  with  peculiar  and  rare 
morphological  features:  numerous  large  asurophilic–bright  red  granules  –  mucopolizaccharides  and 
immunoglobulins secreted and accumulated in the endoplasmic reticulum, typically known as Russel 
bodies.  
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1. Introduction 
 
Multiple  myeloma  is  a  neoplastic  plasma  cell  dyscrasia  characterized  by 
monoclonal proliferation of plasma cells with their accumulation in the bone marrow [1]. 
The malignant plasma cells produce an immunoglobulin (Ig) or protein M, a homogeneous 
Ig, formed of only one type of heavy chain and one type of light chain (kappa or lambda); 
the  immunohistochemical  particularities  of  this  Ig  establish  the  clinical  features  of  the 
disease.  
Diagnostic criteria for multiple myeloma include: more than 10% atypical plasma 
cells in the bone marrow, a monoclonal immunoglobulin in the serum or light
 chains in the 
urine and the presence of osteolytic lesions [2]. 
Anemia, renal insufficiency, hypercalcemia, metabolic dysfunctions and infections 
are all clinical features of the disease, with prognostic value [3, 4].  
 
Myeloma cells have different morphological variants.  
Usually,  bone  marrow  aspirate  shows  clusters  with  a  variable  number  of  plasma 
cells; this underlines the need of careful examination of more than one smear. The bone 
marrow  involvement  is  usually  “focal”.  Solitary  plasma  cell  infiltration  appears  in  rare 
cases [2]. 
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Myeloma cells have distinct morphological criteria: [2, 5, 6] 
Myeloma cells are larger than  reactive plasma cells, with high  nucleo/cytoplasmic 
ratio. The nucleus is displaced from the center of the cell, with nodular chromatin pattern; 
some  of  the  cells  may  present  a  nucleolus  and  a  perinuclear  clear  zone.  Multi  -  or 
binucleated  plasma  cells  are  present.  The  cytoplasm  is  basophilic  with  large 
intracytoplasmic  inclusions  (mucopolysaccharides  and  immunoglobulins  secreted  and 
accumulated in the endoplasmic reticulum), known as Russell bodies, resembling a bunch of 
grapes [2, 7]. Dutcher bodies are PAS positive intranuclear inclusions seen in plasma cells. 
In  myeloma,  there  is  often  discordance  between  nucleus  and  cytoplasm,  the  former 
appearing immature and the latter highly differentiated. There is often a high polymorphism 
– there are seen both abnormal plasma cells, and transitional forms – lymphoplasmacytoid – 
cells with intermediate features between lymphocytes and plasma cells [2].  
Disorders to be considered in the differential diagnosis of multiple myeloma include 
monoclonal  gammopathy  of  undetermined  significance  (MGUS),  smoldering  myeloma, 
plasma  cell  leukemia,  bone  solitary  plasmacytoma,  extramedullar  plasmacytoma,  primary 
amyloidosis, chronic lymphocytic leukemia and bone marrow metastasis [1]. 
   The median survival period after diagnosis is approximately three years. Among the 
prognostic  factors  identified  in  this
  disease  are:  plasma  cell  proliferation  index,  β2 
microglobulin level, C reactive protein, creatinine, lactate dehydrogenase (LDH), low serum 
albumin,  plasmablast  morphology  [8],  abnormal  karyotypes  (the  complete  deletion  of 
chromosome 13) or t (4; 14), t (14;16) translocation [1, 4]. 
 
Although there is virtually no prospect
 of a cure with current therapies (VMCP, VAD 
regimens  etc,  plus  bisphosphonates)  [9,  10,  11,  12,  13],  there  are  several  options  under 
investigation that include combinations of drugs such as Thalidomide, Bortezomib and CC - 
5013  -  Lenalidomide. [12, 14, 15] Several  groups have used VAD followed  by intensive
 
myeloablative therapy with autologous marrow transplantation
 in younger patients [12, 16]. 
 
 
2. Full case presentation 
  
We present the case of an 80 - year - old man, P.N. with percutaneous vertebroplasty 
in February 2007; he was in his usual
 state of health until two months prior to presentation, 
when he
 began to complain of back pain and progressive weakness.   
   A  complete  blood  cell  count  (CBC)
  revealed  normochromic,  normocytic  anemia 
(hemoglobin  7.1  g/dl),  rouleaux  formation  was  appreciated  on  peripheral  blood  smear, 
biological  inflammatory  syndrome  (ESR  60mm/hour,  C  reactive  protein  –  positive),  high 
lactate dehydrogenase (LDH 301U/l), creatinine 3.97mg/dl, BUN 157mg/dl, hypokaliemia 
(K 3.6mmols/l), hypercalcemia (Ca - 10.31mg/dl), hyperuricemia (8mg/dl). Serum protein 
electrophoresis  detected  a  monoclonal  peak  limited  to  the  gamma  region  of  the 
electrophoretic strip (albumin 30%, alpha1 = 2.9%, alpha2 = 14.4%; beta = 8.7%; gamma = 
44%); immunoelectrophoresis showed high values of IgG (35g/l), with low IgA (0.295g/l) 
and IgM (0.497g/l); urine immunofixation detected Bence Jones proteinuria.  
  Bone  marrow  aspiration  was  performed  and  revealed
  a  hypercellular  bone  marrow 
with  increased  plasma  cells  (53%)  with  decreased  granulocytic  and  erythrocytic 
components,  with  a  slight  megaloblastic  deviation,  and  with  present  thrombocytogenic 
megakaryocytes (Figure 1) 
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Figure 1: Clusters of plasma cells can be seen throughout this view of the aspirate  – P.N. case (BM –MGG, 
objective 20X) 
  
Flowcytometry analysis of the bone marrow aspirate is not included in the diagnostic criteria 
of multiple myeloma; in this case, no aberrant phenotype was noted – the profile of plasma cells 
was CD 38+ CD 138+ CD 56+ (favorable prognostic factor) and CD 19 - (Figure 2, 3). 
 
Figure 2: Dot - plot histograms: plasma cells (purple) positive for CD 38, CD 138, CD 56 and negative for CD 19 
(BD Facs - Calibur, Software CellQuest version 3.3) - P.N. case. 
 
 
Figure 3: Dot - plot histograms: plasma cells (green) positive for CD 38, CD 138, CD 56 and negative for CD 65 (BD 
Facs - Calibur, Software CellQuest version 3.3) - P.N. case. Journal of Medicine and Life  Vol. 1, No.1, January-March 2008 
 
 
  77 
 
The particular aspect of this case resides in the morphological features of the  myeloma 
plasma cells (Figures 4 to 7). These are large cells arranged in clusters, with basophilic cytoplasm, 
with  excentrically  placed  nucleus and  a  perinuclear  clear  zone.  The  chromatin  has a  particular 
nodular  pattern;  an  inconstant  nucleolus  may  be  observed.  Plasma  cells  had  numerous  large 
azurophilic  -  bright  red  granules  -  mucopolysaccharides  and  immunoglobulins  secreted  and 
accumulated in the endoplasmic reticulum, typically known as Russel bodies [2, 5, 6].  
Large bi - and multinucleated plasma cell were described.  
 
   
Figure 4a, 4b - Clusters of plasma cells with azurophilic granules (MO  – MGG, 100x objective) - P.N. case 
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Figure 5a, 5b, 5c - Plasma cells with numerous azurophilic granules that tend to cover the nucleus, in some cases 
with cohesive appearance (Auer rods–like) - P.N. case 
 
 
Figure 6 - Plasma cells with numerous azurophilic granules, one binucleated, some granules have foamy aspect 
(MO – MGG, 100x objective) - P.N. case 
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Figure 7a, 7b - Plasma cells with numerous azurophilic granules, some granules have foamy aspect (MO – MGG, 
100x objective) - P.N. case 
 
The investigations were completed with X - rays of the skull which showed multiple lytic
 
cranial  lesions  and  diffuse  osteoporosis  (Figure  8).  Spinal  MRI  scan  identified  of  compression 
fracture of T12, L1, L2 with diffuse osteoporosis (Figure 9). 
 
 
Figure 8 - Skull x - ray showing multiple lytic areas - P.N. case 
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Figure 9 - Spinal MRI scan - compression fracture of T12, L1, L2 with collapsed plateau - P.N. case 
 
The final diagnosis was Multiple
 Myeloma IgG Kappa stage III B; this was established 
according to Salmon-Durie Staging System [17] in the presence of major criteria: 53% myeloma 
plasma cells in bone marrow, monoclonal protein peak in serum, osteolytic
 lesions, corroborated 
with:  anemia,  renal  failure,  hypercalcemia.  The  multiple  myeloma  was  complicated  with 
compression fracture, secondary anemia, and possibly secondary amyloidosis. The renal failure may 
have a combined etiology: amyloidosis, myeloma kidney, excess NSAIDs treatment for back pain.  
With  an  obvious  diagnosis,  the  differential  diagnosis  was  easy  to  establish  [1,  2,  3], 
including: a) monoclonal gammapathy of undetermined significance (MGUS) and b) smoldering 
myeloma, both with monoclonal immunoglobulin in the serum less than 3g/dl, < 10% plasma cells 
in  bone  marrow,  no  evidence  of  myeloma  end  -  organ  damage  -  anemia,  renal  failure, 
hypercalcemia, lytic
 lesions; c) Waldenstrom’s macroglobulinemia with IgM paraprotein peak and 
lymphoplasmacytic bone marrow infiltration [1].  
The patient’s prognosis is unfavorable [1, 4] because of multiple associated factors: age, 
aggressive  onset  of  disease  –  with  complications  (acute  renal  failure,  multiple  lytic  lesions, 
vertebral destructions that needed surgical intervention), associated cardiac pathology which limits 
the possible therapeutic regimens, other biological factors with prognostic value – severe anemia, 
increased LDH, positive PCR. We mention that neither the percentage of plasma cell involvement 
of the bone marrow, nor the morphological aspect of plasma cells represent prognostic factors  – 
except for the case when plasmablasts are observed, or when plasma cells appear on the peripheral 
blood smear (PBS) [1, 4]. 
 
 3. Discussion  
  
Multiple morphological variants of plasma cells are described [2, 5, 6]: 
  Plasma  cells  with  abundant  eosinophilic  cytoplasm  because  of  the  presence  of 
immunoglobulins  as  bright  red  granules  -  Flame  Cells,  frequently  associated  with  IgA 
myeloma; however, they can also be associated with other types of myeloma. 
  Plasma cells with globular inclusions (Russell bodies) in their cytoplasm  – Mott cells – 
resembling a bunch of grapes 
  Plasmablast  –  large  cells  with  a  very  large  nucleus  and  prominent  nucleolus  (adverse 
prognostic factor) 
  Multiple intracellular mitosis and abnormal plasma cells with large nucleus 
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Plasma cells have a great variety of intracytoplasmic or intranuclear inclusions [2, 5, 6, 7]: 
Russell  bodies  (mucopolysaccharides  and  immunoglobulins  secreted  and  accumulated  in  the 
endoplasmic  reticulum),  immunoglobulin  granules  and  large  vacuoles.  These  different  globular 
intracytoplasmic  inclusions  are  often  mistaken  for  Auer  rods  or  liposarcoma  cells,  or  even 
adenocarcinoma cells – the typical aspect is of signet ring cells [6].  
Because  of  the  peculiar  morphological  aspect  of  plasma  cells  presented  in  this  case 
(numerous  large  azurophilic  -  bright  red  granules),  we  considered  necessary  to  have  a  careful 
differential diagnosis with other morphological variants [2, 5, 6, 7] - typical plasma cells (Figure 10, 
11), sarcoma plasma cells like (Figure 13), plasmablasts (Figure 14, 15), foamy plasma cells (Figure 
15), flame cells (Figure 16), Russell bodies (Figure 12) and reactive plasma cells.  
 
The morphological variants of plasma cells are presented below in table 1 (adapted after 6): 
 
Table 1: Different morphological aspects of plasma cells:   
Type  Characteristics 
Plasma cells with or without 
anaplastic 
  high incidence; 
  nucleo/cytoplasmic asynchronism or dysplastic 
characteristics; 
  nucleolus plasma cells; 
  anaplastic morphological type includes: large 
nucleus, polymorphism, morphological aspects 
resembling immunoblastic lymphoma 
Small/lymphocytic cells    central nucleus, abundant or moderate basophilic 
cytoplasm; 
  small incidence 
Lobulated/ 
folded/monocytoid/ 
convoluted 
  small incidence; 
  lobulated nucleus and multiple irregularities; 
  differential diagnosis with T cell leukemia 
Flame Cells    polymorphic cells with eosinophilic cytoplasm 
(Flame Cells); 
  torn cytoplasm cells; 
  multinucleated cells, associated with IgA myeloma, 
but also present in other myeloma types 
Plasmablast    more than 2% blasts with high nucleo/cytoplasmic 
ratio, diffuse chromatin, variable nucleolus 
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Figure 10a, 10b, 10c – Typical plasma cells - cluster cells, eccentrically placed nucleus, nodular chromatin, 
basophilic  cytoplasm,  perinuclear  clear  zone,  some  multinucleated,  others  with  nucleolus  (B.M.  –  MGG,  100x 
objective) – images from “Diagnosis of Hematologic Malignancies - Atlas Notes and Images“, Ana Maria Vlădăreanu, 
Carol Davila Universitary Publishing House, Bucharest, 2007 - Hematology Department – Emergency Universitary 
Hospital Bucharest, with the author’s permission 
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Figure  11  –  Typical  plasma  cells  (nucleus  displaced  from  the  center,  nodular  chromatin,  basophilic 
cytoplasm,  a  perinuclear  clear  zone,  some  multinucleated)  and  lymphoplasma cytoid  cells  (reduced  basophilic 
cytoplasm,  with  high  nucleo/cytoplasmic  ratio)  –  (B.M.  –  MGG,  100x  objective)  –  image  from  “Diagnosis  of 
Hematologic Malignancies - Atlas Notes and Images“, Ana Maria Vlădăreanu, Carol Davila Universitary Publishing 
House, Bucharest, 2007 - Hematology Department – Emergency Universitary Hospital Bucharest, with the author’s 
permission 
 
 
 
 
Figure 12  – Plasma cells with Russell rods (B.M.  – MGG, 100x objective)  – image from “Diagnosis of 
Hematologic Malignancies - Atlas Notes and Images“, Ana Maria Vlădăreanu, Carol Davila Universitary Publishing 
House, Bucharest, 2007 - Hematology Department – Emergency Universitary Hospital Bucharest, with the author’s 
permission 
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Figure  13  –  Plasma  cell  sarcoma  like  (B.M.  –  MGG,  100x  objective)  –  image  from  “Diagnosis  of 
Hematologic Malignancies - Atlas Notes and Images“, Ana Maria Vlădăreanu, Carol Davila Universitary Publishing 
House, Bucharest, 2007 - Hematology Department – Emergency Universitary Hospital Bucharest, with the author’s 
permission 
 
     
Figure 14a, 14b  – Plasmablasts  - high nucleo/cytoplasmatic ratio, some with nucleolus (P.B.S.  – MGG, 
100x  objective)  –  images  from  “Diagnosis  of  Hematologic  Malignancies  -  Atlas  Notes  and  Images“,  Ana  Maria 
Vlădăreanu, Carol Davila Universitary Publishing House, Bucharest, 2007 - Hematology Department – Emergency 
Universitary Hospital Bucharest, with the author’s permission 
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Figure 15a, 15b – Foamy plasma cells, plasmablasts with high nucleo/cytoplasmic ratio (B.M.  – MGG, 100x 
objective  –  images  from  the  cases  diagnosed  in  the  Hematology  Department  –  Emergency  Universitary  Hospital 
Bucharest) 
 
 
Figure 16  – Flame plasma cell (B.M.  – MGG, 100x objective – images from the cases diagnosed in the 
Hematology Department – Emergency Universitary Hospital Bucharest) 
 
 
There  is  a  classification  of  multiple  myeloma  based  on  morphology,  with  important 
implications in evolution and prognosis (table 2) (after 2, adapted after 5): 
 
Table 2: Morphological and prognostic value classification of multiple myeloma  [2, 5]: 
  Reduced malignancy MM: plasmocytic type  
o  Small cells 
  Intermediate malignancy MM: folded type  
o  Polymorphous type  
o  Asynchronic type Journal of Medicine and Life  Vol. 1, No.1, January-March 2008 
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  High malignancy MM: plasmablastic type.  
 
There are situations when it is necessary to make a differential diagnosis between plasma 
cells  and  blast  cells  in  acute  leukemia,  and  other  hematopoietic  precursors  -  osteoblast  -  or 
nonhematopoietic cells (bone marrow metastasis) [2, 5, 6] 
   
4. Conclusions:  
 
The  presented  case  illustrates  the  necessary  diagnostic  steps,  a  typical  combination  of 
clinical features and laboratory tests.  
It is a clear diagnosis: IgG Kappa multiple
 myeloma stage III B with compression fractures of T12, 
L1, L2, secondary anemia, possibly secondary amyloidosis and renal failure. 
The  unusual  aspect  of  this  case  is  the  morphological  facet  of  myeloma  cells  –  with 
numerous  large  azurophilic-bright  red  granules;  this  characteristic,  in  the  light  of  the  multiple 
associated complications, may be regarded as an unfavorable prognostic factor in this particular 
case.  
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